Skip to main content
. 2008 Jul;47(Suppl 4):iv20–iv22. doi: 10.1093/rheumatology/ken166

Table 1.

Anti-fracture efficacy of strontium ranelate

Fracture Duration (yrs) RR (95% CI)
Vertebral 1 0.51 (0.36, 0.74)
Vertebral 3 0.59 (0.48, 0.73)
Vertebral 4 0.67 (0.53, 0.81)
Clinical vertebral 1 0.48 (0.29, 0.80)
Clinical vertebral 3 0.62 (0.47, 0.83)
Non-vertebral 3 0.84 (0.70, 0.99)
Non-vertebral 5 0.85 (0.73, 0.99)
Hip (post hoc)a 3 0.64 (0.41, 0.99)
Hip (post hoc)b 5 0.57 (0.33, 0.97)

aAge >74 yrs; t-score hip ≤ − 2.4 (NHANES). bAge >74 yrs; t-score hip and spine ≤ − 2.4 (NHANES).